Gamida Cell Appoints Terry Coelho as CFO
Gamida Cell, a cell therapy pioneer working to turn cells into powerful therapeutics, has announced the appointment of Terry Coelho as Chief Financial Officer effective immediately. Shai Lankry, who has served as the company’s CFO for the past five years, is stepping down as CFO today and will leave the company June 2.
The transition is part of a planned leadership change first shared with the investor community in August 2022 and designed to coincide with Gamida Cell’s evolution from a clinical to a commercial-stage company. Ms. Coelho is a seasoned finance executive with more than 35 years of experience across all areas of finance at emerging growth companies and established global companies.
“I want to thank Shai for his many contributions supporting the expansion and evolution of the company to include a more robust pipeline and operations in both the United States and Israel,” said Abbey Jenkins, President and Chief Executive Officer. “Terry has tremendous experience as CFO of commercial-stage biopharmaceutical companies. She will be a great partner to help us execute our two-pronged strategy of launching Omisirge and, in parallel, pursuing strategic partnerships to fully resource commercialization.”
Ms. Coelho currently serves as an independent director on the public company boards of First Wave BioPharma (Nasdaq: FWBI) and HOOKIPA Pharma (Nasdaq: HOOK) and she is chairperson of the audit committee and a member of the compensation committees for both companies. She most recently served as Executive Vice President, CFO and Chief Business Development Officer at CinCor Pharma, Inc., where she led the company’s successful initial public offering and follow-on financing in 2022. AstraZeneca acquired CinCor in February.
Ms. Coelho’s experience also includes serving as Executive Vice President and CFO at BioDelivery Sciences International, Inc., which was acquired by Collegium Pharmaceuticals in 2022, and as CFO at Balchem Corporation and Diversey, Inc. She held a series of senior financial and executive roles at Sealed Air Corporation, Mars, Inc. and Novartis Pharmaceuticals, where for seven years she held roles of increasing responsibility including as finance lead for the oncology hematology franchise and later leading global oncology development finance.
“Omisirge has great commercial potential and the opportunity to fill a critical need for patients in need of stem cell transplant,” said Ms. Coelho. “I’m excited to work with the team to help support Omisirge’s launch and find a partner that can help it fulfill its promise.”
Ms. Coelho earned an MBA in Finance from IBMEC in Brazil and Bachelor of Arts degrees in Economics and International Relations, summa cum laude, from The American University School of International Service in Washington, DC.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more